CYP2C18 and PSEN1 |
cytochrome P450, family 2, subfamily C, polypeptide 18 |
presenilin 1 |
- Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
- Defective FMO3 causes Trimethylaminuria (TMAU)
- Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
- Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
- Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
- Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
- Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
- Metabolic disorders of biological oxidation enzymes
- Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
- Phase 1 - Functionalization of compounds
- Defective CYP1B1 causes Glaucoma
- Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
- Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
- Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
- Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
- Xenobiotics
- Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
- Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
- Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
- Cytochrome P450 - arranged by substrate type
- Defective MAOA causes Brunner syndrome (BRUNS)
- Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
- Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
- Biological oxidations
|
- Degradation of the extracellular matrix
|
|
|
|
|
DCTN1 and DISC1 |
dynactin 1 |
disrupted in schizophrenia 1 |
- IRE1alpha activates chaperones
- MHC class II antigen presentation
- XBP1(S) activates chaperone genes
- Unfolded Protein Response (UPR)
- Adaptive Immune System
|
|
|
|
|
|
DMD and DISC1 |
dystrophin |
disrupted in schizophrenia 1 |
- Striated Muscle Contraction
- Non-integrin membrane-ECM interactions
|
|
|
|
|
|
DOCK3 and PSEN1 |
dedicator of cytokinesis 3 |
presenilin 1 |
- Factors involved in megakaryocyte development and platelet production
|
- Degradation of the extracellular matrix
|
|
|
|
|
EFNB2 and PSEN1 |
ephrin-B2 |
presenilin 1 |
- EPHB-mediated forward signaling
- Ephrin signaling
- EPH-ephrin mediated repulsion of cells
- Axon guidance
- EPH-Ephrin signaling
|
- Degradation of the extracellular matrix
|
|
|
|
|
ENSA and PSEN1 |
endosulfine alpha |
presenilin 1 |
- MASTL Facilitates Mitotic Progression
- Mitotic Prophase
- Cell Cycle, Mitotic
- M Phase
|
- Degradation of the extracellular matrix
|
|
|
|
|
ERN1 and PSEN1 |
endoplasmic reticulum to nucleus signaling 1 |
presenilin 1 |
- IRE1alpha activates chaperones
- Unfolded Protein Response (UPR)
|
- Degradation of the extracellular matrix
|
|
|
|
|
FGF13 and PSEN1 |
fibroblast growth factor 13 |
presenilin 1 |
|
- Degradation of the extracellular matrix
|
|
|
|
|
GAPDH and PSEN1 |
glyceraldehyde-3-phosphate dehydrogenase |
presenilin 1 |
- Gluconeogenesis
- Glucose metabolism
- Myoclonic epilepsy of Lafora
- Glycogen storage diseases
- Glycolysis
- Metabolism of carbohydrates
|
- Degradation of the extracellular matrix
|
- NADH
- Nicotinamide-Adenine-Dinucleotide
- Adenosine-5-Diphosphoribose
- Thionicotinamide-Adenine-Dinucleotide
- 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE
|
|
|
|
GSK3B and PSEN1 |
glycogen synthase kinase 3 beta |
presenilin 1 |
- Signaling by the B Cell Receptor (BCR)
- Hedgehog 'off' state
- Signaling by FGFR in disease
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- PI3K/AKT activation
- PI-3K cascade
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- CRMPs in Sema3A signaling
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- APC truncation mutants have impaired AXIN binding
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Regulation of HSF1-mediated heat shock response
- Cellular response to heat stress
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- TCF dependent signaling in response to WNT
- Signaling by Hedgehog
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Degradation of GLI2 by the proteasome
|
- Degradation of the extracellular matrix
|
- Lithium
- 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
- I-5
- N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
- Staurosporine
- Indirubin-3\'-Monoxime
- Adenosine-5\'-Diphosphate
- (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
- Alsterpaullone
- Phosphoaminophosphonic Acid-Adenylate Ester
- 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
- 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
- (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
- 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
- N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
|
|
|
|
HMGB1 and PSEN1 |
high mobility group box 1 |
presenilin 1 |
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Toll Like Receptor TLR1:TLR2 Cascade
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- Activation of DNA fragmentation factor
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- Programmed Cell Death
- MyD88 dependent cascade initiated on endosome
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Toll Like Receptor 9 (TLR9) Cascade
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Apoptotic execution phase
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Apoptosis induced DNA fragmentation
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- TRAF6 mediated NF-kB activation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
- Degradation of the extracellular matrix
|
|
|
|
|
MET and PIK3R1 |
MET proto-oncogene, receptor tyrosine kinase |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
- Axon guidance
- Semaphorin interactions
- Sema4D mediated inhibition of cell attachment and migration
- Sema4D in semaphorin signaling
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Interleukin-7 signaling
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by Interleukins
- TCR signaling
- Signaling by VEGF
- GP1b-IX-V activation signalling
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
- K-252a
- 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
- N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide
- 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide
- N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide
- 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
- 6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline
- 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine
- 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE
- Cabozantinib
|
- Isoproterenol
- (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
|
|
|
NOS3 and PSEN1 |
nitric oxide synthase 3 (endothelial cell) |
presenilin 1 |
- Phagosomal maturation (early endosomal stage)
- VEGFA-VEGFR2 Pathway
- eNOS activation
- Metabolism of nitric oxide
- Platelet homeostasis
- Signaling by VEGF
- VEGFR2 mediated vascular permeability
- NOSTRIN mediated eNOS trafficking
- NOSIP mediated eNOS trafficking
- Latent infection of Homo sapiens with Mycobacterium tuberculosis
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Nitric oxide stimulates guanylate cyclase
- eNOS activation and regulation
|
- Degradation of the extracellular matrix
|
- L-Arginine
- L-Citrulline
- Tetrahydrobiopterin
- Miconazole
- N,N-dimethylarginine
- L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide
- L-2-Amino-4-(Guanidinooxy)Butyric Acid
- 3-Bromo-7-Nitroindazole
- N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N\'-Nitroguanidine
- N-(3-(Aminomethyl)Benzyl)Acetamidine
- 1,2,4-Triazole-Carboxamidine
- L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide
- S,S\'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 7-Nitroindazole
- Ethylisothiourea
- 2-Aminothiazoline
- Se-Ethyl-Isoselenourea
- (6r,1\'r,2\'s)-5,6,7,8 Tetrahydrobiopterin
- 2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine
- N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane
- Hydroxydimethylarsine Oxide
- Heme
- 7-Nitroindazole-2-Carboxamidine
- 6-Nitroindazole
- N-Omega-Hydroxy-L-Arginine
- N5-Iminoethyl-L-Ornithine
- 5,6-Cyclic-Tetrahydropteridine
- S-Ethyl-N-Phenyl-Isothiourea
- S,S\'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 6s-5,6,7,8-Tetrahydrobiopterin
- S-(Dimethylarsenic)Cysteine
- L-Homoarginine
- S-Isopropyl-Isothiourea
- Nitroarginine
- 5-Nitroindazole
- N-(Chlorophenyl)-N\'-Hydroxyguanidine
- (3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine
- 5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE
- ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE
- N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N\'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
- N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N\'-(3-chlorobenzyl)ethane-1,2-diamine
|
|
|
|
NOTCH4 and PSEN1 |
notch 4 |
presenilin 1 |
- Notch-HLH transcription pathway
- Signaling by NOTCH4
- Generic Transcription Pathway
- Pre-NOTCH Processing in Golgi
- Pre-NOTCH Transcription and Translation
- Signaling by NOTCH
- Pre-NOTCH Processing in the Endoplasmic Reticulum
- Pre-NOTCH Expression and Processing
|
- Degradation of the extracellular matrix
|
|
|
|
|
OXCT1 and PSEN1 |
3-oxoacid CoA transferase 1 |
presenilin 1 |
- Ketone body metabolism
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Utilization of Ketone Bodies
|
- Degradation of the extracellular matrix
|
|
|
|
|
PIK3R1 and PSEN1 |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
presenilin 1 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Interleukin-7 signaling
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by Interleukins
- TCR signaling
- Signaling by VEGF
- GP1b-IX-V activation signalling
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
- Degradation of the extracellular matrix
|
- Isoproterenol
- (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
|
|
|
|
PIK3R1 and WAS |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
Wiskott-Aldrich syndrome |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Interleukin-7 signaling
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by Interleukins
- TCR signaling
- Signaling by VEGF
- GP1b-IX-V activation signalling
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
- TCR signaling
- Generation of second messenger molecules
- Fcgamma receptor (FCGR) dependent phagocytosis
- Regulation of actin dynamics for phagocytic cup formation
- Innate Immune System
- Adaptive Immune System
|
- Isoproterenol
- (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
|
|
|
|
PIK3R1 and TGFBR2 |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
transforming growth factor, beta receptor II (70/80kDa) |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Interleukin-7 signaling
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by Interleukins
- TCR signaling
- Signaling by VEGF
- GP1b-IX-V activation signalling
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Isoproterenol
- (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
|
|
|
|
PRKACA and PSEN1 |
protein kinase, cAMP-dependent, catalytic, alpha |
presenilin 1 |
- Signaling by GPCR
- Ca-dependent events
- CaM pathway
- Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
- Metabolism of lipids and lipoproteins
- Integration of energy metabolism
- Hedgehog 'off' state
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Regulation of PLK1 Activity at G2/M Transition
- PLCG1 events in ERBB2 signaling
- Gluconeogenesis
- Glucose metabolism
- DAP12 signaling
- Rap1 signalling
- Myoclonic epilepsy of Lafora
- Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
- Glycogen storage diseases
- PKA-mediated phosphorylation of key metabolic factors
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Recruitment of mitotic centrosome proteins and complexes
- Glucagon signaling in metabolic regulation
- Signaling by PDGF
- Calmodulin induced events
- DAP12 interactions
- PKA-mediated phosphorylation of CREB
- Opioid Signalling
- PKA activation
- Factors involved in megakaryocyte development and platelet production
- Aquaporin-mediated transport
- CREB phosphorylation through the activation of Adenylate Cyclase
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- PKA-mediated phosphorylation of CREB
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by VEGF
- Downstream signal transduction
- Calmodulin induced events
- Signaling by EGFR in Cancer
- Metabolism of carbohydrates
- PKA activation
- Interleukin-3, 5 and GM-CSF signaling
- Mitotic G2-G2/M phases
- Transmission across Chemical Synapses
- Adaptive Immune System
- Organelle biogenesis and maintenance
- G2/M Transition
- VEGFA-VEGFR2 Pathway
- DAG and IP3 signaling
- CaM pathway
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- Loss of Nlp from mitotic centrosomes
- Downstream signaling of activated FGFR
- DARPP-32 events
- Post NMDA receptor activation events
- Innate Immune System
- PKA activation in glucagon signalling
- Signalling by NGF
- PLC beta mediated events
- Vasopressin regulates renal water homeostasis via Aquaporins
- Regulation of insulin secretion
- Cytokine Signaling in Immune system
- Assembly of the primary cilium
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Lipid digestion, mobilization, and transport
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Anchoring of the basal body to the plasma membrane
- Cell Cycle, Mitotic
- Signaling by FGFR
- Loss of proteins required for interphase microtubule organization from the centrosome
- PLC-gamma1 signalling
- Signaling by Hedgehog
- Degradation of GLI1 by the proteasome
- Centrosome maturation
- GLI3 is processed to GLI3R by the proteasome
- Degradation of GLI2 by the proteasome
|
- Degradation of the extracellular matrix
|
|
|
|
|
PRKCZ and PSEN1 |
protein kinase C, zeta |
presenilin 1 |
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by VEGF
- GPVI-mediated activation cascade
- Platelet activation, signaling and aggregation
- SMAD4 MH2 Domain Mutants in Cancer
|
- Degradation of the extracellular matrix
|
|
|
|
|